EC-MPS

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, University Health Network, Toronto, Hoffmann-La Roche

Conditions

Kidney TransplantationOrgan TransplantationPatients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS

Phase 3

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

CompletedNCT00238446

Novartis PharmaceuticalsPatients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS

Start: 2003-04-30Updated: 2017-02-24

Phase 4

Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors

University Health Network, TorontoOrgan Transplantation

Start: 2008-01-31End: 2009-12-31Target: 400Updated: 2009-02-17

A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients

CompletedNCT01033864

Hoffmann-La RocheKidney Transplantation

Start: 2009-11-30End: 2010-06-30Updated: 2015-08-27